Avid Bioservices Inc (CDMO)

[jakedogman1]

BP can sort thru the "noise" and there is a lot of noise

Keytruda and Opdivo would not have been approved if compared to sunrise control arm of 10.8 mths...

https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0153-x

keytruda....

keynote 001 w/ prior therapy MOS for keytruda was 9.3 mths vs 10.7 mths bavi sunrise all patients...

keynote 010 w/ pdl > 1% MOS was 12.7 mths (note real efficacy was pd1 >50%) and control arm was 8.5 mths vs 10.8 mths for sunrise control arm...

opdivo....

Opdivo mos was 12.2 w/ docetaxel arm 9.4 mths

Bavi...

The ESMO results w/ b2gp1 as biomarker (of which b2gp1 as biomarker is a "joke" and they know it) did well and given the pd1 crowd only addresses about 30% of patients and the current theory is bavi plus pd1 makes the pd1 drugs "better"...

so we find out soon what "biomarkers" predict potential bavi success and the big guns such as fox and gerber are all over it...

i have a feeling some of these trial were designed with "noise" to sort the wheat from the chaff and retail is the chaff

BP knows how to keep score....